Company Filing History:
11 out of 49,745 
2 out of 3 
2 out of 187 Years Active: 2016-2024
Title: Youngjun Lee: Innovator in Immunotherapy
Introduction
Youngjun Lee is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of immunotherapy, particularly through his innovative research and development of natural killer (NK) cell therapies. With a total of 13 patents, Lee's work is paving the way for advancements in the treatment of infectious diseases and cancer.
Latest Patents
One of Youngjun Lee's latest patents focuses on a natural killer cell containing exogenous mitochondria and a pharmaceutical composition comprising the same. This invention provides NK cells and peripheral blood mononuclear cells (PBMC) that exhibit increased cytotoxicity. The introduction of exogenous mitochondria into these cells enhances the immune system's ability to combat infectious diseases and cancer. As a result, the NK cells and PBMC can be utilized in compositions aimed at the prevention or treatment of these conditions. Notably, the use of autogenous NK cells and PBMC ensures stability without triggering an immune reaction, which is expected to lead to high commercial viability.
Career Highlights
Throughout his career, Youngjun Lee has worked with notable companies such as LG Electronics Inc. and Paean Biotechnology Inc. His experience in these organizations has contributed to his expertise in the field of biotechnology and immunotherapy.
Collaborations
Some of Youngjun Lee's coworkers include Wanho Ju and Namjin Kim, who have collaborated with him on various projects related to his innovative research.
Conclusion
Youngjun Lee's contributions to immunotherapy through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to inspire advancements in the treatment of serious health conditions, showcasing the potential of innovative therapies.